See more : Mini Diamonds (India) Limited (MINID.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Repligen Corporation (RGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Repligen Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Uttam Sugar Mills Limited (UTTAMSUGAR.NS) Income Statement Analysis – Financial Results
- CDON AB (CDON.ST) Income Statement Analysis – Financial Results
- DiaSorin S.p.A. (DSRLF) Income Statement Analysis – Financial Results
- CP ALL Public Company Limited (CPALL-R.BK) Income Statement Analysis – Financial Results
- Arihant Foundations & Housing Limited (ARIHANT.NS) Income Statement Analysis – Financial Results
Repligen Corporation (RGEN)
About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 632.36M | 801.54M | 670.53M | 366.26M | 270.25M | 194.03M | 141.24M | 104.54M | 83.54M | 63.55M | 68.17M | 62.27M | 27.29M | 20.97M | 29.36M | 19.30M | 14.07M | 12.91M | 9.36M | 6.91M | 7.77M | 4.30M | 2.35M | 3.45M | 2.60M | 2.40M | 3.80M | 10.90M | 16.90M | 26.80M | 27.30M | 11.70M | 7.60M | 12.70M | 8.50M | 10.20M | 3.70M | 3.60M |
| Cost of Revenue | 323.54M | 345.83M | 279.28M | 156.63M | 119.10M | 85.95M | 67.05M | 47.12M | 35.25M | 28.02M | 25.16M | 27.17M | 7.12M | 5.51M | 6.78M | 6.16M | 3.61M | 3.55M | 3.89M | 3.25M | 3.48M | 1.99M | 1.12M | 782.23K | 400.00K | 300.00K | 300.00K | 100.00K | -1.10M | 1.50M | -500.00K | -200.00K | -600.00K | 10.50M | 7.60M | 7.20M | 4.40M | 2.60M |
| Gross Profit | 308.83M | 455.71M | 391.25M | 209.63M | 151.15M | 108.08M | 74.19M | 57.42M | 48.29M | 35.53M | 43.01M | 35.10M | 20.17M | 15.46M | 22.58M | 13.14M | 10.46M | 9.36M | 5.47M | 3.67M | 4.29M | 2.31M | 1.22M | 2.67M | 2.20M | 2.10M | 3.50M | 10.80M | 18.00M | 25.30M | 27.80M | 11.90M | 8.20M | 2.20M | 900.00K | 3.00M | -700.00K | 1.00M |
| Gross Profit Ratio | 48.84% | 56.85% | 58.35% | 57.23% | 55.93% | 55.70% | 52.53% | 54.93% | 57.80% | 55.90% | 63.09% | 56.36% | 73.92% | 73.74% | 76.92% | 68.08% | 74.32% | 72.50% | 58.47% | 53.02% | 55.22% | 53.67% | 52.15% | 77.33% | 84.62% | 87.50% | 92.11% | 99.08% | 106.51% | 94.40% | 101.83% | 101.71% | 107.89% | 17.32% | 10.59% | 29.41% | -18.92% | 27.78% |
| Research & Development | 42.72M | 43.94M | 34.27M | 20.18M | 19.45M | 15.77M | 8.67M | 7.36M | 5.74M | 5.61M | 7.34M | 10.49M | 12.53M | 14.16M | 12.77M | 7.24M | 5.92M | 5.16M | 5.04M | 6.48M | 5.23M | 5.36M | 5.79M | 3.75M | 1.80M | 1.40M | 1.40M | 12.30M | 31.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 65.69M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 0.00 | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 631.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 216.89M | 215.83M | 183.87M | 119.62M | 95.61M | 66.32M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 13.23M | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 4.71M | 4.16M | 2.53M | 2.49M | 2.48M | 1.60M | 1.30M | 2.40M | 4.90M | 4.70M | 42.10M | 37.40M | 23.60M | 15.60M | 3.90M | 3.70M | 3.60M | 3.60M | 3.00M |
| Other Expenses | 0.00 | -9.53M | -1.17M | -214.00K | -314.00K | 262.00K | -687.00K | -860.00K | -445.00K | 188.00K | -110.65K | 26.40K | 1.54B | 1.35M | 1.09M | -40.17M | 0.00 | 0.00 | 0.00 | 2.41M | 0.00 | 0.00 | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| Operating Expenses | 261.12M | 259.77M | 218.14M | 139.80M | 115.06M | 82.09M | 60.18M | 38.21M | 30.44M | 22.76M | 20.04M | 23.72M | 20.55M | 21.23M | 18.70M | -22.76M | 12.28M | 10.58M | 9.63M | 13.61M | 9.39M | 7.89M | 8.56M | 6.56M | 3.70M | 2.90M | 4.00M | 18.60M | 38.30M | 44.50M | 39.10M | 24.70M | 16.50M | 4.70M | 4.30M | 4.10M | 4.20M | 3.50M |
| Cost & Expenses | 584.66M | 605.60M | 497.42M | 296.44M | 234.16M | 168.04M | 127.23M | 85.33M | 65.69M | 50.79M | 45.21M | 50.89M | 27.67M | 26.74M | 25.48M | -16.60M | 15.90M | 14.13M | 13.52M | 16.86M | 12.87M | 9.88M | 9.68M | 7.34M | 4.10M | 3.20M | 4.30M | 18.70M | 37.20M | 46.00M | 38.60M | 24.50M | 15.90M | 15.20M | 11.90M | 11.30M | 8.60M | 6.10M |
| Interest Income | 0.00 | 6.98M | 176.00K | 1.74M | 5.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.03M | 1.16M | 12.71M | 12.13M | 9.29M | 6.71M | 6.44M | 3.77M | 32.00K | 49.96K | 49.85K | 56.71K | 26.17K | 1.97K | 2.96K | 2.96K | 0.00 | 696.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 68.56M | 50.99M | 38.45M | 27.07M | 20.87M | 15.78M | 10.45M | 5.33M | 4.59M | 4.02M | 3.11M | 3.51M | 1.67M | 1.38M | 1.08M | 824.63K | 539.03K | 398.43K | 756.26K | 886.71K | 802.23K | 257.54K | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| EBITDA | 127.77M | 246.93M | 211.56M | 101.62M | 58.43M | 41.77M | 24.14M | 24.55M | 22.44M | 15.16M | 26.13M | 14.84M | -30.47K | 1.66M | -3.52M | 6.85M | 36.72M | -1.83M | -1.22M | -2.23M | -8.66M | -4.29M | -5.32M | -7.06M | -4.04M | -2.46M | -615.02K | -2.80M | -6.40M | -17.70M | -16.80M | -9.60M | -11.70M | -7.40M | -1.70M | -2.80M | -600.00K | -4.30M |
| EBITDA Ratio | 20.20% | 23.03% | 25.64% | 19.01% | 13.24% | 13.53% | 9.43% | 17.56% | 20.83% | 20.38% | 33.52% | 18.32% | 4.77% | -20.92% | 16.88% | -28.53% | -15.87% | -15.42% | -48.96% | -101.69% | -62.40% | -149.65% | -388.18% | -105.49% | -7.69% | -25.00% | -10.53% | -25.69% | -37.87% | -62.69% | -35.16% | -100.00% | -132.89% | -14.17% | -32.94% | -21.57% | 310.81% | -86.11% |
| Operating Income | 47.70M | 133.61M | 133.50M | 42.54M | 14.90M | 25.99M | 14.01M | 15.97M | 13.76M | 10.69M | 22.87M | 11.08M | -374.07K | -5.77M | 3.88M | 35.89M | -1.83M | -1.22M | -4.16M | -9.94M | -5.09M | -5.58M | -7.33M | -3.89M | -1.50M | -800.00K | -500.00K | -7.80M | -20.30M | -19.20M | -11.30M | -12.80M | -8.30M | -2.50M | -3.40M | -1.10M | -4.90M | -2.50M |
| Operating Income Ratio | 7.54% | 16.67% | 19.91% | 11.62% | 5.51% | 13.39% | 9.92% | 15.28% | 16.48% | 16.82% | 33.55% | 17.80% | -1.37% | -27.50% | 13.21% | 186.00% | -12.97% | -9.45% | -44.46% | -143.77% | -65.55% | -129.67% | -312.46% | -112.74% | -57.69% | -33.33% | -13.16% | -71.56% | -120.12% | -71.64% | -41.39% | -109.40% | -109.21% | -19.69% | -40.00% | -10.78% | -132.43% | -69.44% |
| Total Other Income/Expenses | 9.00M | -5.53M | -13.71M | -10.61M | -9.93M | -4.55M | -6.76M | -4.28M | -341.00K | 447.58K | 140.82K | -108.34K | -2.35M | 5.72M | 868.07K | 1.89M | 39.76M | 936.07K | 1.92M | 1.18B | 5.40M | 1.12M | 2.05M | 3.52M | 1.86M | 1.96M | 315.02K | 500.00K | 7.80M | 800.00K | 7.90M | 0.00 | 7.10M | 5.90M | 2.50M | 3.70M | 1.10M | 3.50M |
| Income Before Tax | 56.71M | 219.14M | 153.54M | 59.22M | 26.15M | 21.44M | 7.25M | 11.69M | 13.42M | 11.14M | 23.01M | 11.27M | -43.51K | -4.90M | 5.77M | 37.93M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Income Before Tax Ratio | 8.97% | 27.34% | 22.90% | 16.17% | 9.68% | 11.05% | 5.13% | 11.18% | 16.07% | 17.53% | 33.76% | 18.10% | -0.16% | -23.36% | 19.66% | 196.59% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| Income Tax Expense | 21.11M | 33.18M | 25.25M | -709.00K | 4.74M | 4.82M | -21.11M | 11.00K | 4.08M | 2.97M | 6.92M | -2.88M | -330.56K | -834.77K | 26.70K | 827.47K | 889.26K | -696.86K | 2.98M | 9.55M | 4.54M | 4.46M | 5.28M | 3.82M | 2.50M | 800.00K | 500.00K | 11.50M | 32.00M | 19.50M | 11.30M | 12.80M | 5.70M | 2.40M | 3.30M | -300.00K | 20.70M | 1.40M |
| Net Income | 35.60M | 185.96M | 128.29M | 59.93M | 21.41M | 16.62M | 28.35M | 11.68M | 9.35M | 8.17M | 16.09M | 14.16M | -43.51K | -4.06M | 5.75M | 37.11M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Net Income Ratio | 5.63% | 23.20% | 19.13% | 16.36% | 7.92% | 8.56% | 20.07% | 11.17% | 11.19% | 12.86% | 23.61% | 22.73% | -0.16% | -19.38% | 19.57% | 192.30% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| EPS | 0.64 | 3.35 | 2.33 | 1.14 | 0.44 | 0.38 | 0.74 | 0.35 | 0.28 | 0.25 | 0.51 | 0.46 | 0.00 | -0.13 | 0.19 | 1.20 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.75 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| EPS Diluted | 0.63 | 3.24 | 2.24 | 1.11 | 0.44 | 0.37 | 0.72 | 0.34 | 0.28 | 0.25 | 0.50 | 0.45 | 0.00 | -0.13 | 0.18 | 1.18 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.74 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| Weighted Avg Shares Out | 55.72M | 55.46M | 55.02M | 52.55M | 48.34M | 43.77M | 38.23M | 33.57M | 32.88M | 32.50M | 31.67M | 30.91M | 30.78M | 30.75M | 30.96M | 30.83M | 30.38M | 30.13M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.37M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
| Weighted Avg Shares Out (Dil) | 56.38M | 57.46M | 57.26M | 53.89M | 49.21M | 45.47M | 39.15M | 34.10M | 33.58M | 33.26M | 32.41M | 31.25M | 30.78M | 30.75M | 31.29M | 31.32M | 30.38M | 30.69M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.53M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
Exclusive: Repligen in bid for reagent vendor Maravai, sources say
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday.
Here's Why Shares in This Hot Healthcare Stock Surged This Week
A far larger peer backs up Repligen's market commentary. Bioprocessing customers are working through inventory, and orders growth is bouncing back.
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
Repligen Corporation RGEN reported in-line earnings for its second quarter on Tuesday.
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates
Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024.
Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript
Repligen Corporation [RGEN] Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Tony Hunt - CEO Jason Garland - CFO Olivier Loeillot - President & CCO Sondra Newman - IR Conference Call Participants Rachel Vatnsdal -...
Repligen Lowers Guidance On China Weakness, Analyst Expects
Tuesday, Repligen Corporation RGEN reported second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million.
Repligen (RGEN) Q2 Earnings Meet Estimates
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.53 per share a year ago.
Repligen Reports Second Quarter 2024 Financial Results
WALTHAM, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) of 2024, covering the three- and six- month periods ended June...
Repligen Announces Agreement to Acquire Chromatography Innovator Tantti
WALTHAM, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Tantti Laboratory Inc. (“Tantti”) of Taoyuan City,...
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports